Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August

Rhea-AI Summary

Aileron Therapeutics (NASDAQ: ALRN) announced that CEO Manuel Aivado will take part in two investor conferences in August 2020. The first event is the William Blair Biotech Focus Conference on August 6 at 12:00 pm ET, featuring a fireside chat. The second event is the Canaccord Genuity 40th Annual Growth Conference on August 13 at 4:30 pm ET, where Aivado will provide a company overview and business update. Live webcasts will be available on Aileron's website, and recordings will be archived for 30 days.

Aileron focuses on advancing ALRN-6924, a treatment aimed at reducing chemotherapy side effects.

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month.

Thursday, August 6, 2020
Event: William Blair Biotech Focus Conference 2020
Time:  12:00 pm ET
*Fireside chat

Thursday, August 13, 2020
Event: Canaccord Genuity 40^th Annual Growth Conference
Time:  4:30 pm ET
*Company overview and business update presentation

Live webcasts of these events will be available under the Investors and Media section of Aileron’s website at https://investors.aileronrx.com/. A replay of the webcasts will be archived on Aileron’s website for 30 days following the respective events.

About Aileron Therapeutics

At Aileron, we are focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.

In addition to potentially reducing or eliminating multiple side effects, ALRN-6924 may also improve patients’ quality of life and help them better tolerate chemotherapy, potentially allowing patients to complete their treatment without dose reductions or delays. Our long-term vision is to provide chemoprotection for patients with p53-mutated cancers, which represents approximately 50% of cancer patients, regardless of cancer type or chemotherapeutic drug. Visit us at aileronrx.com to learn more. 

Investor Contacts:

Aileron Therapeutics
Richard Wanstall, SVP Chief Financial Officer
617-995-0900
rwanstall@aileronrx.com

Hans C. Vitzthum
LifeSci Advisors, LLC.
617-430-7578
hans@lifesciadvisors.com

Media Contact:
Liz Melone
617-256-6622
lmelone@aileronrx.com

FAQ

What are the details of Aileron Therapeutics' investor conferences in August 2020?

Aileron Therapeutics will participate in two investor conferences in August 2020. The William Blair Biotech Focus Conference is on August 6 at 12:00 pm ET, followed by the Canaccord Genuity 40th Annual Growth Conference on August 13 at 4:30 pm ET.

Where can I watch the webcasts for Aileron Therapeutics' investor conferences?

The live webcasts for Aileron Therapeutics' investor conferences will be available under the Investors and Media section of their website. Replays will also be archived for 30 days after each event.

What is the purpose of ALRN-6924 in Aileron Therapeutics' research?

ALRN-6924 is designed to protect healthy cells during chemotherapy, potentially reducing side effects and improving the quality of life for cancer patients with p53 mutations.

Who will represent Aileron Therapeutics at the upcoming investor conferences?

Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will represent Aileron Therapeutics during the investor conferences.